ArticleNature communications2014
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.
2 registry-linked trialsOpen access · bronzeAbstract read
In one paragraph
Article in Nature communications, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 573 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
573citing papers in PubMed, 3 pooled it
53.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Study
In Situ Clonal Heterogeneity in Prostatic Diagnostic Biopsies: Impact on Prostate Cancer Evolution and Clinical Outcome. A Retrospective, Proof of Concept Study
Who cites it
573 citing papers in PubMed, 3 syntheses or guidelines pooled it, 895 citations in OpenAlex.
- Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data.Cancer immunology, immunotherapy : CII · 2024Pooled it
- Efficacy and safety of Venetoclax-based regimens in relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials.Annals of medicine · 2023Pooled it
- Clinical Significance of Circulating Cell-Free DNA Detection in Multiple Myeloma: A Meta-Analysis.Frontiers in oncology · 2022Pooled it
- The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.Blood cancer journal · 2024Trial
- Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma.Leukemia · 2022Trial
- Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.Blood advances · 2021Trial
- Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy.Nature medicine · 2026Article
- Dual targeting of BCMA and GPRC5D with the trispecific antibody ramantamig addresses antigenic heterogeneity in myeloma.HemaSphere · 2026Article
- A single-cell atlas of multiple myeloma defines malignant archetypes and proliferative states.Nature genetics · 2026Article
- Prognostic Significance of Cell-Free DNA Derived 5-Hydroxymethylcytosine Signatures in Newly Diagnosed Multiple Myeloma.JCO precision oncology · 2026Article
- Genetic architecture of multiple myeloma: From somatic alterations to germline susceptibility and clinical implications.Translational oncology · 2026Review
- The Shape-Shifting Myeloma: Adaptive Plasticity as a Hallmark of Relapse and Refractoriness.Cancers · 2026Review
- The Evolving Role of Genomic Technologies in Multiple Myeloma: Implications for Diagnosis, Risk Stratification and Resistance.Molecular diagnosis & therapy · 2026Review
- Review
- Allogeneic hematopoietic stem cell transplantation in ERCC6L2 disease.Blood advances · 2026Article
- Dynamic cytogenetic evolution in multiple myeloma: prognostic implications from diagnosis to first relapse.The oncologist · 2026Article
- Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability.Blood advances · 2026Article
- Genome-wide copy number profiling enhances risk stratification in multiple myeloma by shallow whole-genome sequencing.Blood advances · 2026Article
- Next-Generation Biomarkers in Multiple Myeloma: Advancing Diagnosis, Risk Stratification, and Precision Therapy Beyond Current Guidelines.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Integrated RNA-seq and RT-qPCR Workflow Identifies Non-IGH Fusion Transcripts as Individualized Molecular Markers for Monitoring Multiple Myeloma.Biomedicines · 2026Article
513 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 8 institutions in 3 countries.
Niccolo Bolli1] Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK [2] Department of Haematology, University of Cambridge, CIMR, Cambridge CB2 0XY, UK.
Hervé Avet-Loiseau1] Unité de Génomique du Myélome, CHU Rangueil, Toulouse 31059, France [2] CRCT, INSERM U1037, Toulouse 31400, France.
David C WedgeCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
Peter Van Loo1] Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK [2] Department of Human Genetics, VIB and University of Leuven, Leuven 3000, Belgium.
Ludmil B AlexandrovCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
Inigo MartincorenaCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
Kevin J DawsonCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
Francesco Iorio1] Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK [2] European Molecular Biology Laboratory-European Bioinformatics Institute, Hinxton CB10 1SA, UK.
Serena Nik-Zainal1] Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK [2] Department of Medical Genetics, Addenbrooke's Hospital NHS Trust, Cambridge CB2 0QQ, UK.
Graham R BignellCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
Jonathan W HintonCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
Yilong LiCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
Jose M C TubioCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
Stuart McLarenCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
Sarah O' MearaCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
Adam P ButlerCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
Jon W TeagueCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
Laura MudieCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
Elizabeth AndersonCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK.
Naim RashidLebow Institute of Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Yu-Tzu TaiLebow Institute of Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Masood A Shammas1] Lebow Institute of Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA [2] Boston Veterans Administration Healthcare System, West Roxbury, Massachusetts 02132, USA.
Adam S SperlingLebow Institute of Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Mariateresa FulcinitiLebow Institute of Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Paul G RichardsonLebow Institute of Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Giovanni ParmigianiDana-Farber Cancer Institute and Harvard School of Public Health, Boston, Massachusetts 02115, USA.
Florence Magrangeas1] Center for Cancer Research Nantes-Angers, UMR 892 Inserm-6299 CNRS-University of Nantes, IRS-UN, Nantes 4407, France [2] UMGC, University Hospital, Nantes 44093, France.
Stephane Minvielle1] Center for Cancer Research Nantes-Angers, UMR 892 Inserm-6299 CNRS-University of Nantes, IRS-UN, Nantes 4407, France [2] UMGC, University Hospital, Nantes 44093, France.
Philippe MoreauDepartment of Hematology, University Hospital, Nantes 44093, France.
Michel AttalDepartment of Hematology, University Hospital and CRCT, INSERM U1037, Toulouse 31400, France.
Thierry FaconDepartment of Hematology, University Hospital, Lille 59045, France.
P Andrew Futreal1] Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK [2].
Kenneth C AndersonLebow Institute of Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Peter J Campbell1] Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK [2] Department of Haematology, University of Cambridge, CIMR, Cambridge CB2 0XY, UK.
Nikhil C Munshi1] Lebow Institute of Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA [2] Boston Veterans Administration Healthcare System, West Roxbury, Massachusetts 02132, USA.
Wellcome Sanger Institute · GBDana-Farber Cancer Institute · USCentre de Recherche en Cancérologie et Immunologie Intégrée Nantes Angers · FRCentre de Recherche en Cancérologie de Toulouse · FRHôpital Rangueil · FRLille’s Cardiology Hospital · FRUniversity of Cambridge · GBVA Boston Healthcare System · US
Funding
Trageting the Multiple Myeloma EpigenomeP50CA100707 · NCI · DANA-FARBER CANCER INSTITUTE · PI ANDERSON, KENNETH C., MUNSHI, NIKHIL C. · 2003 to 2023
$45.0MTargeting Genomic Instability and Evolution in MyelomaP01CA155258 · NCI · DANA-FARBER CANCER INST · PI Jill Corre · 2011 to 2026
$32.5MTargeting Myeloma Cell-Host Bone Marrow InteractionsP01CA078378 · NCI · DANA-FARBER CANCER INSTITUTE · PI WELLER, EDIE A · 1998 to 2014
$26.2MBiostatistics for Research in Genomics and CancerT32CA106209 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JOSEPH G IBRAHIM, Naim Ur Rashid · 2004 to 2026
$4.8MTelomerase And Homologous Recombination As Targets In Barrett's AdenocarcinomaR01CA125711 · NCI · WAYNE STATE UNIVERSITY · PI SHAMMAS, MASOOD A · 2008 to 2012
$1.7MMOLECULAR MANIPULATION TO ENHANCE ANTI-MYELOMA RESPONSEI01BX001584 · VA · VA BOSTON HEALTH CARE SYSTEM · PI MUNSHI, NIKHIL C. · 2013 to 2025
–BLRD VA I01 BX001584NCI NIH HHS P01 CA078378NCI NIH HHS P01 CA155258NCI NIH HHS P50 CA100707NCI NIH HHS R01 CA125711NCI NIH HHS T32 CA106209PHS HHS P01-155258PHS HHS P01-78378PHS HHS P50-100007PHS HHS R01-124929PHS HHS RCA125711CWellcome Trust 077012/Z/05/ZWellcome Trust 088340
Abstract
Multiple myeloma is an incurable plasma cell malignancy with a complex and incompletely understood molecular pathogenesis. Here we use whole-exome sequencing, copy-number profiling and cytogenetics to analyse 84 myeloma samples. Most cases have a complex subclonal structure and show clusters of subclonal variants, including subclonal driver mutations. Serial sampling reveals diverse patterns of clonal evolution, including linear evolution, differential clonal response and branching evolution. Diverse processes contribute to the mutational repertoire, including kataegis and somatic hypermutation, and their relative contribution changes over time. We find heterogeneity of mutational spectrum across samples, with few recurrent genes. We identify new candidate genes, including truncations of SP140, LTB, ROBO1 and clustered missense mutations in EGR1. The myeloma genome is heterogeneous across the cohort, and exhibits diversity in clonal admixture and in dynamics of evolution, which may impact prognostic stratification, therapeutic approaches and assessment of disease response to treatment.
Indexed as
ExomeAdultAgedAntigens, NuclearCohort StudiesDNA Copy Number VariationsEarly Growth Response Protein 1Evolution, MolecularGenetic HeterogeneityGTP PhosphohydrolasesHumansLymphotoxin-betaMembrane ProteinsMiddle AgedMultiple MyelomaMutationAntigens, NuclearBRAF protein, humanEarly Growth Response Protein 1EGR1 protein, humanGTP PhosphohydrolasesKRAS protein, humanLTB protein, humanLymphotoxin-betaMembrane ProteinsNerve Tissue ProteinsNRAS protein, humanProto-Oncogene ProteinsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)ras ProteinsReceptors, ImmunologicRoundabout ProteinsSP140 protein, humanTP53 protein, humanTranscription FactorsTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT03421132ClinicalTrials.gov
NCT04873427ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.